These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 19318419)

  • 1. Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells.
    Levy EM; Sycz G; Arriaga JM; Barrio MM; von Euw EM; Morales SB; González M; Mordoh J; Bianchini M
    Innate Immun; 2009 Apr; 15(2):91-100. PubMed ID: 19318419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer.
    Levy EM; Bianchini M; Von Euw EM; Barrio MM; Bravo AI; Furman D; Domenichini E; Macagno C; Pinsky V; Zucchini C; Valvassori L; Mordoh J
    Int J Oncol; 2008 Mar; 32(3):633-41. PubMed ID: 18292941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines.
    Kurai J; Chikumi H; Hashimoto K; Yamaguchi K; Yamasaki A; Sako T; Touge H; Makino H; Takata M; Miyata M; Nakamoto M; Burioka N; Shimizu E
    Clin Cancer Res; 2007 Mar; 13(5):1552-61. PubMed ID: 17332301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
    Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
    Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour antigen targeted monoclonal antibodies incorporating a novel multimerisation domain significantly enhance antibody dependent cellular cytotoxicity against colon cancer.
    Jain A; Poonia B; So EC; Vyzasatya R; Burch EE; Olsen HS; Mérigeon EY; Block DS; Zhang X; Schulze DH; Hanna NN; Twadell WS; Yfantis HG; Chan SL; Cai L; Strome SE
    Eur J Cancer; 2013 Oct; 49(15):3344-52. PubMed ID: 23871153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between antibody-dependent cell-mediated cytotoxicity due to anti-HTLV-1 and negative signal of major histocompatibility complex class I antigens on adult T-cell leukemia cell lines.
    Komatsu F; Tamiya H
    Oncol Res; 1998; 10(2):59-67. PubMed ID: 9666513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C.
    Braud VM; Allan DS; O'Callaghan CA; Söderström K; D'Andrea A; Ogg GS; Lazetic S; Young NT; Bell JI; Phillips JH; Lanier LL; McMichael AJ
    Nature; 1998 Feb; 391(6669):795-9. PubMed ID: 9486650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of CD85j in TNBC patients inhibits Cetuximab-mediated NK-cell ADCC but can be restored with CD85j functional blockade.
    Roberti MP; Juliá EP; Rocca YS; Amat M; Bravo AI; Loza J; Coló F; Loza CM; Fabiano V; Maino M; Podhorzer A; Fainboim L; Barrio MM; Mordoh J; Levy EM
    Eur J Immunol; 2015 May; 45(5):1560-9. PubMed ID: 25726929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease.
    Bellone S; Frera G; Landolfi G; Romani C; Bandiera E; Tognon G; Roman JJ; Burnett AF; Pecorelli S; Santin AD
    Gynecol Oncol; 2007 Sep; 106(3):513-20. PubMed ID: 17540437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma.
    Kawaguchi Y; Kono K; Mimura K; Sugai H; Akaike H; Fujii H
    Int J Cancer; 2007 Feb; 120(4):781-7. PubMed ID: 17096332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR.
    Roberti MP; Barrio MM; Bravo AI; Rocca YS; Arriaga JM; Bianchini M; Mordoh J; Levy EM
    Breast Cancer Res Treat; 2011 Nov; 130(2):465-75. PubMed ID: 21308409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts.
    Damiano V; Caputo R; Garofalo S; Bianco R; Rosa R; Merola G; Gelardi T; Racioppi L; Fontanini G; De Placido S; Kandimalla ER; Agrawal S; Ciardiello F; Tortora G
    Proc Natl Acad Sci U S A; 2007 Jul; 104(30):12468-73. PubMed ID: 17636117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA-E/human beta2-microglobulin transgenic pigs: protection against xenogeneic human anti-pig natural killer cell cytotoxicity.
    Weiss EH; Lilienfeld BG; Müller S; Müller E; Herbach N; Kessler B; Wanke R; Schwinzer R; Seebach JD; Wolf E; Brem G
    Transplantation; 2009 Jan; 87(1):35-43. PubMed ID: 19136889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased frequency of human leukocyte antigen-E inhibitory receptor CD94/NKG2A-expressing peritoneal natural killer cells in patients with endometriosis.
    Galandrini R; Porpora MG; Stoppacciaro A; Micucci F; Capuano C; Tassi I; Di Felice A; Benedetti-Panici P; Santoni A
    Fertil Steril; 2008 May; 89(5 Suppl):1490-6. PubMed ID: 17706207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KIR/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity.
    Terszowski G; Klein C; Stern M
    J Immunol; 2014 Jun; 192(12):5618-24. PubMed ID: 24795454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab.
    Pander J; Heusinkveld M; van der Straaten T; Jordanova ES; Baak-Pablo R; Gelderblom H; Morreau H; van der Burg SH; Guchelaar HJ; van Hall T
    Clin Cancer Res; 2011 Sep; 17(17):5668-73. PubMed ID: 21788356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors.
    Della Chiesa M; Vitale M; Carlomagno S; Ferlazzo G; Moretta L; Moretta A
    Eur J Immunol; 2003 Jun; 33(6):1657-66. PubMed ID: 12778484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC.
    Inagaki A; Ishida T; Yano H; Ishii T; Kusumoto S; Ito A; Ri M; Mori F; Ding J; Komatsu H; Iida S; Ueda R
    Int J Cancer; 2009 Jul; 125(1):212-21. PubMed ID: 19358282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients.
    Roberti MP; Rocca YS; Amat M; Pampena MB; Loza J; Coló F; Fabiano V; Loza CM; Arriaga JM; Bianchini M; Barrio MM; Bravo AI; Domenichini E; Chacón R; Mordoh J; Levy EM
    Breast Cancer Res Treat; 2012 Dec; 136(3):659-71. PubMed ID: 23065032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies.
    Riemer AB; Kurz H; Klinger M; Scheiner O; Zielinski CC; Jensen-Jarolim E
    J Natl Cancer Inst; 2005 Nov; 97(22):1663-70. PubMed ID: 16288119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.